Becker's Healthcare June 9, 2023
HHS has added 25 drugs to its list of products eligible for Inflation Reduction Act rebates.
As part of the Inflation Reduction Act, the federal government can levy fines against drug manufacturers who raise the cost of drugs covered by Medicare Part B higher than the rate of inflation.
Some Medicare members will see lower coinsurance costs between $1 to $443 per dose for drugs subject to inflation rebates, according to CMS.
In a June 2 news release, the agency listed 43 drugs subject to reduced copays for Medicare beneficiaries between July 1 and September 30.
The agency named 25 new drugs to the list, and 18 drugs subject to rebates in the first quarter of 2023...
Today's Sponsors
Today's Sponsor